Zepbound Demonstrates Cost Savings Beyond Drug Price

Eli Lilly and Company (LLY)'s marketed obesity treatment Zepbound (tirzepatide), a GIP·GLP-1 dual agonist, showed that the monthly healthcare costs for patients who remained on continuous treatment were up to USD 181 lower at 6 months and USD 607 lower at 12 months in real-world data for overweight or obese patients aged 55 and above. The cost difference was driven by reduced hospitalizations and emergency room visits, providing evidence that drug costs should be evaluated in the context of total healthcare spending. With the global obesity drug market forecasted to reach USD 95 billion by 2030, economic data is becoming a differentiator in insurance coverage competition between Novo Nordisk (NVO)'s Wegovy (semaglutide) and Zepbound.

Ivonescimab Challenges Standard Care for Biliary Tract Cancer

Akeso, Inc. (9926.HK) and Summit Therapeutics Inc. (SMMT)'s ivonescimab (AK112), a bispecific antibody targeting PD-1 and VEGF, met its primary endpoint of overall survival in a pre-specified interim analysis of the Phase 3 HARMONi-GI1 trial in China. Ivonescimab combined with chemotherapy demonstrated clinically meaningful and statistically significant survival benefits compared to AstraZeneca PLC (AZN)'s marketed standard therapy Imfinzi (durvalumab, a PD-L1 inhibitor) combined with chemotherapy. The Independent Data Monitoring Committee declared early success. As the first positive Phase 3 trial outside of lung cancer, ivonescimab's potential in the USD 5.7 billion first-line biliary tract cancer market enhances its value for label expansion.

Imaavy Becomes First FDA-Approved Treatment for wAIHA

Johnson & Johnson (JNJ)'s Imaavy (nifocalimab-aahu), an FcRn antibody that blocks the recycling of pathogenic IgG, was approved by the FDA on August 24, 2026, for warm autoimmune hemolytic anemia (wAIHA) in patients aged 12 and older with prior steroid treatment. In the Phase 2/3 ENERGY trial, Imaavy demonstrated sustained hemoglobin response improvement compared to placebo and became the first FDA-approved treatment for a disease affecting approximately 1 in 8,000 patients in the U.S. Following its first FDA approval in April 2025 for generalized myasthenia gravis and subsequent European approval in November 2025, Imaavy has expanded its label lead over competitors such as argenx (ARGX)'s Vepoloximab.

McKesson Expands Vertical Integration with Precision Medicine Services

McKesson Corporation (MCK) agreed on August 25, 2026, to acquire Precision Medicine Group, LLC for approximately USD 2.25 billion. The acquired company specializes in oncology and rare disease-focused clinical trial CRO services and commercialization support, allowing McKesson to expand its revenue streams from pharmaceutical distribution into clinical development and market access support. The transaction is subject to customary closing conditions, with the company's strategy centered on combining low-margin distribution with high-value-added pharmaceutical services.

Haisco's NewCo Deal and Ophthalmology Combination Therapy Advance in Parallel

Haisco Pharmaceutical Group Co., Ltd. (002653.SZ) transferred the rights to an oral small molecule candidate for Type 2 inflammatory diseases outside the Chinese region to Sentivera Therapeutics, Inc., securing USD 40 million in cash, a 17.5% equity stake worth USD 35.89 million, potential milestone payments up to USD 1.46 billion, and mid-single to low-double-digit royalty rates based on net sales. The candidate is a preclinical asset with Chinese clinical trial approval, and the NewCo structure combining upfront cash and equity strengthens long-term value sharing. Separately, Bausch + Lomb Corporation (BLCO) is advancing a dry eye combination therapy of Xiidra (lifitegrast, an LFA-1 antagonist) and Miebo (perfluorohexyloctane), which failed its primary endpoint in a 29-day Phase 2 trial but showed superiority in a pre-specified 15-day assessment, prompting plans for a Phase 3 trial using the 15-day endpoint.